$1.77
-0.18-9.23%
Last update: Oct 30, 4:00 PM
Seres Therapeutics Inc (MCRB) Stock Price, Quote, News & History
MCRBNASDAQ
Seres Therapeutics reported early SER-155 data, with 80% of patients achieving steroid-free clinical response by Day 15.
You can purchase shares of Seres Therapeutics (NASDAQ:MCRB) through any online brokerage.
Other companies in Seres Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Seres Therapeutics has a consensus price target of $13.75.
The stock price for Seres Therapeutics (NASDAQ: MCRB) is $1.8 last updated October 28, 2026 at 4:03 AM EDT.
There are no upcoming dividends for Seres Therapeutics.
Seres Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Seres Therapeutics.
Seres Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections,...
